An HIV-negative 50-year old man who had undergone heart transplantation in 2009 and kidney transplantation in December 2018 was referred to our hospital in July 2019 due to a disseminated nodular rash which involved the palms, arms, legs, trunk and face ([Fig. 1](#fig0005){ref-type="fig"}). The nodules were bright red and painful to the touch. He had fatigue but no fever or other symptoms. Leucocyte count 12.1\*10\^9/L, neutrophils 9.5\*10\^9/L, C-reactive protein 10 mg/L (ref. \< 10 mg/L). Ultrasound scan of the abdomen revealed splenomegaly 17 cm. Histological exam of biopsies of the skin lesions showed proliferation of ectatic capillaries with neutrophil infiltration and leukocytoclastic debris ([Fig. 2](#fig0010){ref-type="fig"}). PCR of the biopsy was positive for *Bartonella henselae*. Blood serology showed *Bartonella henselae* IgG titer 8000, IgM \<20. The rash improved on treatment with doxycycline 100 mg BID. He did not have pets or recall bites or scratches of cats or dogs, but his mother, who he sometimes visited, had both a cat and a dog.Fig. 1Characteristic tumor-like skin lesions in a solid organ transplant recipient with bacillary angiomatosis.Fig. 1Fig. 2Histological exam showed a tumour-like vasoproliferative lesion with epitheloid endothelial cells, neutrophil infiltration and nuclear dust.Fig. 2

Bacillary angiomatosis is an uncommon disease characterized by neovascular proliferation caused by infection with *Bartonella henselae* or *Bartonella quintana*. Bacillary angiomatosis was first described in patients with HIV and CD4 cell counts \<100/μL, but also occur in patients with other causes of immune deficiency. The disease usually manifests as skin tumors, and may involve other organs, most commonly the spleen and liver, known as peliosis. The involvement of internal organs can lead to fatal disease. Diagnosis is based on histology, culture, PCR and serology. The optimal antibiotic regimen and treatment duration for bacillary angiomatosis has not been established. Most authors recommend prolonged treatment (usually 12 weeks) of doxycycline or macrolide with addition of rifampicin or gentamycin for patients with severe disease. Recurrence after treatment is not rare. Suppressive therapy may be considered for patients with relapse after therapy and continuous immunosuppression.
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